Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation

Stem Cells Translational Medicine

Volumn 1, Issue 5, 2012, Pages 422-429

  Tran, Chy Anh ^a   Torres Coronado, Monica ^a   Gardner, Agnes ^a   Gu, Angel ^a   Vu, Hieu ^a   Rao, Anitha ^a   Cao, Lan Feng ^a   Ahmed, Amira ^a   Digiusto, David ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cellular therapy; Immunodeficient mouse; Stem cell

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; GROWTH FACTOR; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; APHERESIS; ARTICLE; BLOOD CELL COUNT; CELL DIFFERENTIATION; CELL SEPARATION; CELL VIABILITY; CENTRIFUGATION; CONTROLLED STUDY; COUNTER FLOW CENTRIFUGAL ELUTRIATION TECHNIQUE; DRUG PURIFICATION; ENGRAFTMENT; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PROCESS OPTIMIZATION; SEPARATION TECHNIQUE; ADULT; ANIMAL; CYTOLOGY; IMMUNOMAGNETIC SEPARATION; INSTRUMENTATION; METABOLISM; METHODOLOGY; NONOBESE DIABETIC MOUSE; STANDARD;

ADULT; ANIMALS; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL SEPARATION; CENTRIFUGATION; HUMANS; IMMUNOMAGNETIC SEPARATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED NOD; MONOCYTES; PHENOTYPE;

EID: 84872100290     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2011-0062     Document Type: Article

References (43)

1. Scheding S, Brugger W, Mertelsmann R et al. Peripheral blood stem cells: In vivo biology and therapeutic potential. STEM CELLS 1994; 12(suppl 1):203-210; discussion 211.
2. Berenson RJ, Shpall EJ, Auditore-Hargreaves K et al. Transplantation of CD34 hematopoietic progenitor cells. Cancer Invest 1996;14:589-596.
3. Johnson RJ, Owen RG, Smith GM et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996;17:723-727.
4. Handgretinger R, Greil J, Schürmann U et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997;6:235-242.
5. Somlo G, Sniecinski I, Odom-Maryon T et al. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood 1997;89: 1521-1528.
6. Handgretinger R, Lang P, Schumm M et al. Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting. Bone Marrow Transplant 1998;21:987-993.
7. Gandhi M, Jestice H, Scott M et al. A comparison of CD34 cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: A case controlled analysis. Bone Marrow Transplant 1999;24:369-375.
8. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858-1868.
9. Barese CN, Dunbar CE. Contributions of gene marking to cell and gene therapies. Hum Gene Ther 2011;22:659 668.
10. Yannaki E, Papayannopoulou T, Jonlin E et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe-thalassemia: Results of clinical trials using GCSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 2012;20: 230-238.
11. Papanikolaou E, Georgomanoli M, Stamateris E et al. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells. Hum Gene Ther 2012;23:15-31.
12. Gaspar HB, Cooray S, Gilmour KC et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011;3:97-80.
13. Frittoli MC, Biral E, Cappelli B et al. Bone marrow as a source of hematopoietic stem cells for human gene therapy of -thalassemia. Hum Gene Ther 2011;22:507-513.
14. DiGiusto DL, Krishnan A, Li L et al. RNA- based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010;2:36-43.
15. Sumiyoshi T, Holt NG, Hollis RP et al. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther 2009;20:1607-1626.
16. Procházka V, Gumulec J, Jalůvka F et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010;19:1413-1424.
17. Kolvenbach R, Kreissig C, Cagiannos C et al. Intraoperative adjunctive stem cell treatment in patients with critical limb ischemia using a novel point-of-care device. Ann Vasc Surg 2010;24:367-372.
18. Murphy MP, Lawson JH, Rapp BM et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg 2011;53:1565-1574.e1.
19. Pai M, Spalding D, Xi F et al. Autologous bone marrow stem cells in the treatment of chronic liver disease. Int J Hepatol 2012;2012: 307165.
20. Quyyumi AA, Waller EK, Murrow J et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011;161:98-105.
21. He H, Cao J, Wang D et al. Gene-modified stem cells combined with rapid prototyping techniques: A novel strategy for periodontal regeneration. Stem Cell Rev 2010;6:137-141.
22. Losordo DW, Henry TD, Davidson C et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011;109: 428-436.
23. Zimmet H, Porapakkham P, Porapakkham P et al. Shortand long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: A meta-analysis of randomized control trials. Eur J Heart Fail 2012;14:91-105.
24. Abrahamsen TG, Carter CS, Read EJ et al. Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher 1991; 6:48-53.
25. Stevenson HC. Isolation of human mononuclear leukocyte subsets by countercurrent centrifugal elutriation. Methods Enzymol 1984;108:242-249.
26. Persidsky MD, Ling NS. Separation of platelet-rich plasma by modified centrifugal elutriation. J Clin Apher 1982;1:18-24.
27. Contreras TJ, Jemionek JF, French JE et al. Human granulocyte isolation by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation (CFCL/CCE). Transfusion 1979;19:695-703.
28. Ito Y, Suaudeau J, Bowman RL. New flowthrough centrifuge without rotating seals applied to plasmapheresis. Science 1975;189: 999-1000.
29. Micklethwaite KP, Garvin FM, Kariotis MR et al. Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivity. Cytotherapy 2009;11: 218-228.
30. Perseghin P, D'Amico G, Dander E et al. Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device. Transfusion 2008;48:1644-1649.
31. You Y, Xia LH, Zhang C et al. Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: Report of 5 cases [in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87:3127-3129.
32. Lemarie C, Sugaye R, Kaur I et al. Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods 2007; 318:30-36.
33. Kasow KA, Sims-Poston L, Eldridge P et al. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients. Biol Blood Marrow Transplant 2007;13:608-614.
34. Erdmann M, Dörrie J, Schaft N et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 2007;30:663-674.
35. Schwanke U, Nabereit A, Moog R. Isolation of monocytes from whole blood-derived buffy coats by continuous counter-flow elutriation. J Clin Apher 2006;21:153-157.
36. Huang W, Tan W, Zhong Q et al. Development of a gene therapy based bone marrow purging system for leukemias. Cancer Gene Ther 2005;12:873-883.
37. Hiwase DK, White DL, Powell JA et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010;24: 771-778.
38. Zinno F, Landi F, Aureli V et al. Positive immunomagnetic CD34(+) cell selection in haplo-identical transplants in beta-thalassemia patients: Removal of platelets using an automated system. Cytotherapy 2010;12:60-66.
39. Giancola R, Olioso P, Di Riti M et al. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer. Transfusion 2008;48: 629-639.
40. Mullally A, Ritz J. Beyond HLA: The significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007;109:1355-1362.
41. Lemarie C, Calmels B, Malenfant C et al. Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate. Transfusion 2005;45:737-742.
42. Perotti CG, Del Fante C, Viarengo G et al. A new automated cell washer device for thawed cord blood units. Transfusion 2004;44: 900-906.
43. Calmels B, Houzé P, Hengesse JC et al. Preclinical evaluation of an automated closed fluid management device: Cytomate, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transplant 2003;31:823-828.